8-K current report · filed Aug 5, 2026

Entrada Therapeutics, Inc. (TRDA) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1TRDA overview

Short answer

Entrada Therapeutics, Inc. (TRDA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026.

Entrada Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026
  • Financial details and corporate updates contained in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 net loss $42.8M, or $1.01 per share, versus $43.1M and $1.04 in Q2 2025
  • Cash, equivalents and marketable securities $223.0M, down from $295.7M, funding operations into Q3 2027
  • ELEVATE-45-201 Cohort 1 data expected October 2026, with Cohort 2 dosing ongoing at 10 mg/kg
  • ELEVATE-44-201 Cohort 1 open-label data expected by year-end 2026, Cohort 2 data in Q1 2027
  • Vertex VX-670 Phase 1/2 DM1 data expected in H2 2026, providing a partnered clinical catalyst

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Entrada Therapeutics, Inc. 8-K filings

Get the next TRDA 8-K as it lands

Follow TRDA for push alerts, or ask the research agent what this filing means.